



## Pharmacyclics Completes Enrollment in Phase I ANTRIN® Trial For Atherosclerosis

Sunnyvale, Ca. (PRNewswire)

April 27, 1999

Pharmacyclics, Inc. (Nasdaq: [PCYC](#)) today announced that it has completed enrollment in its phase I study with ANTRIN® photoangioplasty for patients with atherosclerotic peripheral arterial disease.

The phase I trial enrolled 50 patients with symptomatic atherosclerosis involving the major arteries of the lower extremities. The two-part study was designed to first, establish an optimum dose of ANTRIN by treating successive cohorts of patients with increasing single doses of the drug. In the second part of the study, three doses of light were evaluated at several drug dose levels. ANTRIN was given intravenously and treatment with light was delivered to the diseased vessel through a 0.89mm optical fiber placed using standard percutaneous endovascular techniques. Patients were evaluated for toxicity and local arterial responses by follow-up angiograms and intravascular ultrasound (IVUS) performed 28 days following photoangioplasty.

The study was conducted at both Stanford University Medical Center, Stanford, California and the Mid-America Heart Institute in Kansas City, Missouri. Interim results from the study were presented at the meeting of the Society of Cardiovascular Interventional Radiology (SCVIR) in March 1999. Using IVUS, it was reported that 12 of 14 evaluable patients responded to treatment, defined as an increase of greater than 10% in the blood vessel opening or minimal luminal diameter (MLD). Responding patients had increases in MLD up to 76% with a mean of 35%.

"The phase I drug and light dosage optimization data is now being incorporated in our preparations for the phase II studies in peripheral artery disease, which are expected to begin later this year," stated Daniel Adelman, M.D., senior director of clinical research at Pharmacyclics. "We expect to present the complete phase I results later this summer."

Pharmacyclics is a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy and chemotherapy of cancer, and to enable or improve the photodynamic therapy of certain cancers, atherosclerotic cardiovascular disease and diseases of the retina. The company's products are ring-shaped small molecules, called "texaphyrins," which are patented agents derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. The texaphyrins localize in cancer cells, atherosclerotic plaque and neovasculature, where they can be activated by various forms of energy, including X-rays, light and chemotherapeutics, to eliminate diseased tissue.

The statements made in this press release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the company's expectations. In addition to the matters described in this release, future actions by the U.S. Food and Drug Administration and other domestic and foreign regulatory agencies, the initiation, timing and results of pending or future clinical trials, as well as risk factors listed from time to time in the company's reports as filed with the U.S. Securities and Exchange Commission, including but not limited to, its reports on Forms 10-Q and 10-K, may affect the actual results achieved by the company.

NOTE: Pharmacyclics®, the "pentadentate" logo® and ANTRIN® are trademarks of Pharmacyclics, Inc.